CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS
· Delayed Price · Currency is USD
3.150
+0.005 (0.96%)
Apr 23, 2025, 4:00 PM EDT
CSPC Pharmaceutical Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 29,009 | 31,450 | 30,937 | 27,867 | 24,942 | Upgrade
|
| Revenue Growth (YoY) | -7.76% | 1.66% | 11.02% | 11.73% | 12.84% | Upgrade
|
| Cost of Revenue | 8,711 | 9,273 | 8,680 | 6,732 | 6,257 | Upgrade
|
| Gross Profit | 20,299 | 22,177 | 22,256 | 21,135 | 18,685 | Upgrade
|
| Selling, General & Admin | 9,742 | 10,330 | 11,510 | 11,453 | 10,323 | Upgrade
|
| Research & Development | 5,191 | 4,830 | 3,987 | 3,433 | 2,890 | Upgrade
|
| Operating Expenses | 14,933 | 15,161 | 15,497 | 14,886 | 13,213 | Upgrade
|
| Operating Income | 5,366 | 7,016 | 6,760 | 6,249 | 5,472 | Upgrade
|
| Interest Expense | -43.67 | -25.9 | -24.89 | -7.66 | -12.23 | Upgrade
|
| Interest & Investment Income | 232.5 | 259.88 | 242.53 | 183.24 | 102.82 | Upgrade
|
| Earnings From Equity Investments | -89.47 | -54.2 | -15.4 | 22.44 | 13.53 | Upgrade
|
| Currency Exchange Gain (Loss) | 19.79 | 102.53 | 118.13 | -35.96 | -127.47 | Upgrade
|
| Other Non Operating Income (Expenses) | 221.31 | 246.21 | 315.32 | 172.63 | 43.17 | Upgrade
|
| EBT Excluding Unusual Items | 5,707 | 7,545 | 7,395 | 6,584 | 5,492 | Upgrade
|
| Gain (Loss) on Sale of Investments | -104.47 | -90.62 | 266.41 | 323.94 | 625.99 | Upgrade
|
| Gain (Loss) on Sale of Assets | -23.4 | -22.23 | -7.36 | -10.79 | 283.48 | Upgrade
|
| Asset Writedown | - | -42.32 | -72.11 | -50 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -10.42 | Upgrade
|
| Pretax Income | 5,579 | 7,389 | 7,582 | 6,847 | 6,391 | Upgrade
|
| Income Tax Expense | 1,240 | 1,317 | 1,350 | 1,159 | 1,162 | Upgrade
|
| Earnings From Continuing Operations | 4,339 | 6,073 | 6,232 | 5,688 | 5,229 | Upgrade
|
| Minority Interest in Earnings | -10.79 | -199.37 | -140.66 | -82.94 | -69.36 | Upgrade
|
| Net Income | 4,328 | 5,873 | 6,091 | 5,605 | 5,160 | Upgrade
|
| Net Income to Common | 4,328 | 5,873 | 6,091 | 5,605 | 5,160 | Upgrade
|
| Net Income Growth | -26.31% | -3.58% | 8.67% | 8.63% | 38.92% | Upgrade
|
| Shares Outstanding (Basic) | 11,738 | 11,872 | 11,917 | 11,953 | 11,955 | Upgrade
|
| Shares Outstanding (Diluted) | 11,738 | 11,873 | 11,919 | 11,954 | 11,956 | Upgrade
|
| Shares Change (YoY) | -1.14% | -0.38% | -0.29% | -0.01% | -0.00% | Upgrade
|
| EPS (Basic) | 0.37 | 0.49 | 0.51 | 0.47 | 0.43 | Upgrade
|
| EPS (Diluted) | 0.37 | 0.49 | 0.51 | 0.47 | 0.43 | Upgrade
|
| EPS Growth | -25.47% | -3.21% | 9.00% | 8.64% | 38.92% | Upgrade
|
| Free Cash Flow | - | 2,555 | 5,407 | 3,226 | 5,383 | Upgrade
|
| Free Cash Flow Per Share | - | 0.21 | 0.45 | 0.27 | 0.45 | Upgrade
|
| Dividend Per Share | 0.244 | 0.254 | 0.191 | 0.152 | 0.107 | Upgrade
|
| Dividend Growth | -3.87% | 33.07% | 25.66% | 41.58% | 13.25% | Upgrade
|
| Gross Margin | 69.97% | 70.51% | 71.94% | 75.84% | 74.91% | Upgrade
|
| Operating Margin | 18.50% | 22.31% | 21.85% | 22.43% | 21.94% | Upgrade
|
| Profit Margin | 14.92% | 18.68% | 19.69% | 20.11% | 20.69% | Upgrade
|
| Free Cash Flow Margin | - | 8.12% | 17.48% | 11.58% | 21.58% | Upgrade
|
| EBITDA | 6,285 | 7,934 | 7,611 | 6,974 | 6,156 | Upgrade
|
| EBITDA Margin | 21.66% | 25.23% | 24.60% | 25.02% | 24.68% | Upgrade
|
| D&A For EBITDA | 918.47 | 918.47 | 851.62 | 724.39 | 683.74 | Upgrade
|
| EBIT | 5,366 | 7,016 | 6,760 | 6,249 | 5,472 | Upgrade
|
| EBIT Margin | 18.50% | 22.31% | 21.85% | 22.43% | 21.94% | Upgrade
|
| Effective Tax Rate | 22.23% | 17.82% | 17.81% | 16.93% | 18.18% | Upgrade
|
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.